Standards & guidance

Filter Standards and Guidance documents

Page 8 of 13

FSRH Clinical Guideline: Overweight, Obesity and Contraception (April 2019)

01 April 2019

This guideline summarises the available evidence on contraceptive choices for women who are overweight and women with obesity (i.e. with body mass index 25 kg/m2 or higher). The guideline evaluates the interrelationship between contraception and weight and considerations such as bariatric surgery and weight loss medication. Also available in digital format on the BMJ website:  FSRH Guideline (April 2019) Overweight, Obesity and Contraception. BMJ Sexual & Reproductive Health 2019; 45:Suppl 2.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH/BASHH Standards for Online and Remote Providers of Sexual and Reproductive Health Services - January 2019

24 January 2019

The rapid expansion in the number of providers of online Sexual and Reproductive Health/Sexual and Reproductive Healthcare (SH/SRH) services has enabled and empowered users to access their healthcare in more ways than through a face-to-face consultation with the health care professional. The FSRH and BASHH support these innovations and recognise that these services have enormous potential. They are seeking, however, key assurances in the standards of care and quality of services provided.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

01 September 2018

A Danish database study suggests that children born to women who have used hormonal contraception (HC) in the three months prior to conception or in early pregnancy are at increased risk of developing childhood non-lymphoid leukaemia compared with children whose mothers have never used HC. The FSRH CEU provides a critical appraisal of the study in this statement.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

01 March 2018

Much recent media attention has been given to the subject of a potential association between hormonal contraception and depression. The FSRH CEU monitors and reports relevant emerging evidence.A new systematic review published in Contraception examines the existing evidence relating to risk of depression associated with use of progestogen-only contraception (POC).1 The authors of the review conclude that the bulk of the evidence does not support an association between use of POC and depression based on validated measures. Meta-analysis was not possible due to the heterogeneity of studies.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids (February 2018)

01 February 2018

The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have been placed on commencing treatment with Esmya and guidelines for monitoring liver function in women already taking Esmya have been introduced. The EMA recommendations are available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002902.jsp&mid=WC0b01ac058004d5c1

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Contraception for women using known teratogenic drugs or drugs with potential teratogenic effects (February 2018)

01 February 2018

This statement provides guidance on contraceptive options for women taking (or whose male partners are taking) known teratogenic drugs or drugs with potential teratogenic effects. Download the full document and save.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Service Standard for Supporting Doctors' Appraisal and Revalidation in SRH - January 2018

24 January 2018

The standard gives practical guidance on how to complete annual appraisal for those healthcare professionals working in SRH full time and for those where it makes up part of their portfolio of work. Guidance includes advice on completing CPD requirements and core activities relevant to SRH.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Response to Study: Intrauterine Contraception Use and Cervical Cancer Risk (January 2018)

01 January 2018

This statement responds to a recent study that reported that women who had used intrauterine contraception (IUC) were over one third less likely to experience invasive cervical cancer than women who had not used IUC. The study has received media attention and the FSRH CEU considered it important to put the findings into perspective. January 2018

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date